Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications

  • Neiberg de Alcantara Lima Western Michigan University Homer Stryker – School of Medicine – Internal Medicine – Kalamazoo (MI), USA/Hospital de Messejana – Departamento de Cardiologia – Fortaleza (CE), Brasil. https://orcid.org/0000-0003-3616-435X
  • Pedro Yuri Paiva Lima McGill University – Department of Cardiology – Montreal, Canada
  • Ricardo Lessa de Castro Junior Western Michigan University Homer Stryker – School of Medicine – Internal Medicine – Kalamazoo (MI), USA/Hospital de Messejana – Departamento de Cardiologia – Fortaleza (CE), Brasil.
  • Eric Martin Sieloff Western Michigan University Homer Stryker – School of Medicine – Internal Medicine – Kalamazoo (MI), USA.
  • Stela Maria Vitorino Sampaio Hospital de Messejana – Departamento de Cardiologia – Fortaleza (CE), Brasil.
Keywords: Coronavirus; Pandemics; Renin–angiotensin system; Angiotensin-converting enzyme inhibitors; COVID-19.

Abstract

Initially reported in China at the end of 2019, the coronavirus pandemic has now reached an international scale with more than 1.5 million cases worldwide and more than eighty thousands deaths by April 8th of this year. Recent studies have shown that the virus invades host cells by the angiotensin-converting enzyme 2 receptor, making it essential to viral transmission. Concerns have been raised about possible benefits and harms associated with the use of ACE inhibitors and angiotensin receptors blockers in these patients. However, there is lack of evidence to recommend even temporarily discontinuing renin-angiotensin system inhibitors/blockers in patients infected with the SARS-CoV-2.

Downloads

Download data is not yet available.

References

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-4.https://doi.org/10.1016/S1473-3099(20)30120-1

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648-55. https://doi.org/10.1161/CIRCULATIONAHA.120.046941

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80. https://doi.org/10.1016/j.cell.2020.02.052

Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiol. Published online March 27, 2020. https://doi.org/10.1001/jamacardio.2020.1286

Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):256-60. https://doi.org/10.1038/s41569-020-0360-5

Cohn JN, Johnson G, Ziesche S, Cobb F, Francis GS, Tristani F, et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303-10. https://doi.org/10.1056/NEJM199108013250502

The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. https://doi.org/10.1056/NEJM198706043162301

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. https://doi.org/10.1056/NEJM199108013250501

The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685-91. https://doi.org/10.1056/NEJM199209033271003

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-17. https://doi.org/10.1056/NEJM199909023411001

Pitt B, Remme WJ, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. https://doi.org/10.1056/NEJMoa030207

Kuhn JH, Li W, Choe H, Farzan M. What’s new in the renin–angiotensin system? Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. CMLS, Cell Mol Life Sci. 2004;61(21):2738-43. https://doi.org/10.1007/s00018-004-4242-5

Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin–angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757-60. https://doi.org/10.1080/22221751.2020.1746200

Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-74. https://doi.org/10.1007/s11427-020-1643-8

Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009;15(7):565-71. https://doi.org/10.1016/j.cardfail.2009.01.014

Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. EP Europace. 2017;19(8):1280-7. https://doi.org/10.1093/europace/euw246

Ramchand J, Patel SK, Kearney LG, Matalanis G, Farouque O, Srivastava PM, et al. Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc Imaging. 2020;13(3):655-64. https://doi.org/10.1016/j.jcmg.2019.09.005

Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28(1):15-21. https://doi.org/10.1093/ajh/hpu086

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. https://doi.org/10.1056/NEJMoa2002032

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. https://doi.org/10.1001/jamainternmed.2020.0994

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. https://doi.org/10.1016/S0140-6736(20)30566-3

Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chin J Cardiol. 2020;48:E004. https://doi.org/10.3760/cma.j.cn112148-20200220-00105

Helmrich SP, Ragland DR, Leung RW, Paffenbarger Junior RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325(3):147-52. https://doi.org/10.1056/NEJM199107183250302

Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown Junior EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction — results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327(10):669-77. https://doi.org/10.1056/NEJM199209033271001

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Junior DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. https://doi.org/10.1161/CIR.0b013e31829e8776

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. Erratum for: Eur Heart J. 2018;39(14):1206. https://doi.org/10.1093/eurheartj/ehx158

Comitê Coordenador da Diretriz de Insuficiência Cardíaca. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol. 2018;111(3):436-539.

Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61-73.https://doi.org/10.1016/S0140-6736(18)32484-X

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–115. https://doi.org/10.1161/HYP.0000000000000065

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. Erratum for: Eur Heart J. 2019;40(5):475. https://doi.org/10.1093/eurheartj/ehy686

Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brandão AA, Neves MFT, et al. 7ª Diretriz Brasileira de Hipertensão Arterial. Arq Bras Cardiol. 2016;107(3):1-83.

Corbo JM, Delellis TM, Hill LG, Rindfuss SL, Nashelsky J. ACE Inhibitors or ARBs to prevent CKD in patients with microalbuminuria. Am Fam Physician. 2016;94(8):652-3.

Published
18-05-2020
How to Cite
Lima, N. de A., Paiva Lima, P. Y., Castro Junior, R. L. de, Sieloff, E. M., & Vitorino Sampaio, S. M. (2020). Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications. JOURNAL OF CARDIAC ARRHYTHMIAS, 33(1), 01-05. Retrieved from https://www.jca.org.br/jca/article/view/3367
Section
SPECIAL SECTION- COVID -19